PuraCath Medical Presents Data on the Company’s Proprietary Infection Reduction Technology during the National Science Foundation’s SBIR Phase II Grantee Conference

Atlanta, Georgia (June 2, 2015) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients on dialysis therapy, announced today that the company was a featured presenter during the National Science Foundation’s (NSF) Small Business Innovation Research (SBIR) 2015 Phase II Grantee Conference held in Atlanta, Georgia. PuraCath presented data from research funded by a NSF SBIR Phase II grant for the project “Novel Peritoneal Dialysis Catheter to Reduce Infections” which demonstrated the ability to reduce bacterial growth in a simulated peritoneal dialysis delivery system when combining ultraviolet (UV) light with a UV transmissible connection system.

“PuraCath is honored to be selected to present data summarizing the results of studies with our technology which was funded by a generous Phase II and IIB grant associated with the NSF’s SBIR Grant program,” said Julia Rasooly, PuraCath Medical’s CEO. “We are proud to have been a recipient and the primary investigator for Phase I, IB, II and IIB NSF SBIR Grants with a total cumulative grant amount of $1.3 million. This non-­‐ dilutive funding, which has supported research and development initiatives for our proprietary technology to date, is a testimony to the medical need to reduce infectious complications in patients on PD therapy.”

“The support PuraCath Medical has received via NSF SBIR grants has permitted the Company to further demonstrate the clinical potential its UV light-­‐based technology has to reduce infectious complications in patients on peritoneal dialysis, allowing further growth in the use of this patient-­‐friendly and higher quality of life, lifesaving therapy,” stated nephrologist Glenn Chertow, M.D. “The ability of PuraCath’s management team to successfully obtain sequential SBIR Grants and the subsequent development of the company’s technology is a testimony to their ability to deliver results and the validates the company’s approach to improve patient outcomes in patients on dialysis therapy.

WHAT IS PERITONEAL DIALYSIS?
Peritoneal dialysis is a home-­‐based dialysis therapy that offers patients a more flexible and physiologically smoother dialysis option. Unlike hemodialysis, peritoneal dialysis uses a patient’s peritoneal membrane to remove toxins and excess fluid from a patient. Peritoneal dialysis therapy permits patients to have a more regular diet and more flexible treatment times, improving their quality of life. Currently there are nearly
40,000 peritoneal patients on dialysis therapy in the U.S. with the number of patients on this therapy increasing over the past several years. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall (peritonitis).

ABOUT PURACATH MEDICAL
PuraCath Medical is a company based in San Francisco, CA and is dedicated to improving the quality of life of patients on dialysis therapy by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. The Company utilizes technology that was spun out of Stanford University and is developing a novel easy-­‐to-­‐use technology designed to reduce infections and improve outcomes for patients on PD therapy. For more information on PuraCath Medical, please visit www.puracath.com.